

INTEGRATED BIOPHARMA INC  
Form NT 10-Q  
February 16, 2016  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

Commission File Number 001-31668

(Check One):	0 Form 10-K	Form
11-K	Form 20-F	x Form 10-Q
		Form N-SAR
For Period Ending: <u>December 31, 2015</u>		
Transition Report on Form 10-K		
Transition Report on Form 10-Q		
Transition Report on Form 20-F		
Transition Report on Form N-SAR		
Transition Report on Form 11-K		

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

Full name of registrant: Integrated BioPharma,  
Inc.

Address of principal executive office (Street and number): 225 Long Avenue

City, State and Zip Code: Hillside, New Jersey 07205

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check appropriate box.)

T (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

(b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report on transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached is applicable.

Part III. Narrative

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period. (Attached extra sheets if needed.)

The Company's Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2015 cannot be filed within the prescribed time period because the Company is experiencing delays in the collection and compilation of certain information required to be included in the Form 10-Q. The Company's Quarterly Report on Form 10-Q will be filed on or before the fifth calendar day following the prescribed due date.

---

Part IV. Other Information

(1) Name and telephone number of person to contact in regard to this notification

Julie Albinsky (212) 592-1524  
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

T Yes No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes T No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

INTEGRATED BIOPHARMA, INC.

(Name of registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 16, 2016 By: /s/ Dina L. Masi

Name: Dina L. Masi

Title: Chief Financial Officer & Senior Vice President